Here are some top research studies our products are developed upon.


Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study.

Background: Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.
Objective: To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).
Methods: Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.
Results: Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p< 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.

More Research Supporting Light Therapy

"PBM was shown to be a safe and potentially effective treatment. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected." / BMC Neurology

How does light therapy offer neurological protection in Parkinson's disease? / NCBI

Treating the microbiome to affect changes in Parkinson’s patients. / Science Direct

Michael R Hamblin, 19 May 2017, Mechanisms and Applications of the Anti-inflammatory effects of Photobiomodulation, AIMS Biophysics Journal

Strong evidence identifying inhibition of nerve function as a mechanism for the clinical application of PBM in pain and anesthesia. / Mary Ann Liebert, Inc

Exciting new microbiome research / SYMBX Biome

Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson's
Disease: A Case Series Conducted During Lockdown / Pub Med

Chronic Pain is Surprisingly Treatable / The Washington Post

Can Light Therapy improve cognition? New research published in Aging & Disease
Journal says that it can! A great article by Suvi Mahonen / SYMBX Biome

Great new article in The Guardian about Chronic Pain by Linda Geddes / The Guardian

New scientific evidence of our Gut-Brain Axis / SYMBX Biome

Understanding Gut Inflammation May Hold Clues to Mitigating Parkinson’s Onset, /

Parkinson’s disease: from the gut to the brain. Infrared light may improve the gut’s
microbiome / Suvi Mahonen

Progress in unravelling the mystery of the genomics of Parkinson's disease / IOS Press

Why Light Therapy?

Light therapy is the non-thermal delivery of waves of light energy with a therapeutic benefit. SYMBYX’s medical-grade lasers are easy to use at home and ARTG/CE listed for reduction in many symptoms.

View More